Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 4, 2009, Pages

  Peña Silva, Ricardo A ^a,b   Miller, Jordan D ^a   Chu, Yi ^a   Heistad, Donald D ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSIDAD DE LOS ANDES   (Colombia)

Author keywords

Carcinoid syndrome; Reactive oxygen species; Serotonin; Superoxide; Valvulopathy

Indexed keywords

APOCYNIN; CLORGYLINE; DIPHENYLIODONIUM SALT; DOPAMINE; FENFLURAMINE; LUCIGENIN; MONOAMINE OXIDASE INHIBITOR; QUERCETIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SEROTONIN; TRANYLCYPROMINE;

ARTICLE; CARCINOID SYNDROME; CHEMOLUMINESCENCE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HOMOGENATE; HUMAN; HUMAN TISSUE; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTIOXIDANTS; DOPAMINE; HEART VALVES; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXIDATIVE STRESS; RECOMBINANT PROTEINS; SEROTONIN; SUPEROXIDES;

EID: 70349617848     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00570.2009     Document Type: Article

References (62)

1. Alper G, Girgin FK, Ozgonul M, Mentes G, Ersoz B. MAO inhibitors and oxidant stress in aging brain tissue. Eur Neuropsychopharmacol 9: 247-252, 1999. (Pubitemid 29114931)
2. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation 116: 2860-2865, 2007.
3. Bianchi P, Pimentel DR, Murphy MP, Colucci WS, Parini A. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB J 19: 641-643, 2005. (Pubitemid 40471271)
4. Billett EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology 25: 139-148, 2004.
5. Blatchford D, Holzbauer M. Ontogenesis of enzyme systems deaminating different monoamines. Br J Pharmacol 57: 279-293, 1976.
6. Britigan BE, Pou S, Rosen GM, Lilleg DM, Buettner GR. Hydroxyl radical is not a product of the reaction of xanthine oxidase and xanthine. The confounding problem of adventitious iron bound to xanthine oxidase. J Biol Chem 265: 17533-17538, 1990. (Pubitemid 20355898)
7. Chrissobolis S, Didion SP, Kinzenbaw DA, Schrader LI, Dayal S, Lentz SR, Faraci FM. Glutathione peroxidase-1 plays a major role in protecting against angiotensin II-induced vascular dysfunction. Hypertension 51: 872-877, 2008. (Pubitemid 351654698)
8. Chu Y, Heistad DD, Knudtson KL, Lamping KG, Faraci FM. Quantification of mRNA for endothelial NO synthase in mouse blood vessels by real-time polymerase chain reaction. Arterioscler Thromb Vasc Biol 22: 611-616, 2002.
9. Coatrieux C, Sanson M, Negre-Salvayre A, Parini A, Hannun Y, Itohara S, Salvayre R, Auge N. MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. Free Radic Biol Med 43: 80-89, 2007. (Pubitemid 46874846)
10. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine- phentermine. N Engl J Med 337: 581-588, 1997. (Pubitemid 27360757)
11. Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD, Pellikka PA. Surgical management of left-sided carcinoid heart disease. Circulation 104: I36-I40, 2001. (Pubitemid 32884774)
12. Cote F, Fligny C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 10: 232-238, 2004. (Pubitemid 38581796)
13. Daws LC, Montanez S, Owens WA, Gould GG, Frazer A, Toney GM, Gerhardt GA. Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry. J Neurosci Methods 143: 49-62, 2005. (Pubitemid 40348789)
14. Disatian S, Orton EC. Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease. J Heart Valve Dis 18: 44-51, 2009.
15. Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N. 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60: 253-262, 2008.
16. Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation 99: 156-161, 1999.
17. Gentili F, Pizzinat N, Ordener C, Marchal-Victorion S, Maurel A, Hofmann R, Renard P, Delagrange P, Pigini M, Parini A, Giannella M. 3-[5-(4,5-dihydro- 1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J Med Chem 49: 5578-5586, 2006. (Pubitemid 44373188)
18. Goedert M, Otten U, Suda K, Heitz PU, Stalder GA, Obrecht JP, Holzach P, Allgower M. Dopamine, norepinephrine and serotonin production by an intestinal carcinoid tumor. Cancer 45: 104-107, 1980. (Pubitemid 10214963)
19. Grewal JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL. Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: proliferative and fibrotic signals. Am J Physiol Renal Physiol 276: F922-F930, 1999.
20. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 111: 1517-1522, 2005. (Pubitemid 40470647)
21. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, Levy RJ. Serotonin mechanisms in heart valve disease I: serotonin-induced upregulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 161: 2111-2121, 2002. (Pubitemid 35434857)
22. Katayama M, Kobayashi S, Oguchi K, Yasuhara H. Properties of monoamine oxidase in monkey heart. Jpn J Pharmacol 35: 425-431, 1984. (Pubitemid 14092064)
23. Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem 40: 86-95, 1994. (Pubitemid 24050218)
24. Kerstein MD, Cronau LH, Mandel SD, Gillis CN. Effect of hemorrhagic shock on 5-hydroxytryptamine removal by the lung. Am Surg 48: 644-646, 1982. (Pubitemid 13202216)
25. Kunduzova OR, Bianchi P, Pizzinat N, Escourrou G, Seguelas MH, Parini A, Cambon C. Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion. FASEB J 16: 1129-1131, 2002.
26. 2 signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 281: L646-L652, 2001.
27. Lee SL, Wang WW, Fanburg BL. Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J 15: 1324-1325, 2001.
28. Lee SL, Wang WW, Finlay GA, Fanburg BL. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol Lung Cell Mol Physiol 277: L282-L291, 1999.
29. Liu Y, Fanburg BL. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serinethreonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. Am J Respir Cell Mol Biol 34: 182-191, 2006.
30. Liu Y, Li M, Warburton RR, Hill NS, Fanburg BL. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J 21: 2725-2734, 2007. (Pubitemid 47372740)
31. Maurel A, Hernandez C, Kunduzova O, Bompart G, Cambon C, Parini A, Frances B. Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am J Physiol Heart Circ Physiol 284: H1460-H1467, 2003. (Pubitemid 36348611)
32. McCord JM, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem 243: 5753-5760, 1968.
33. McCormick DL, Spicer AM, Hollister JL. Differential effects of tranylcypromine and imidazole on mammary carcinogenesis in rats fed low and high fat diets. Cancer Res 49: 3168-3172, 1989. (Pubitemid 19162119)
34. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, haiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113: 81-89, 2006.
35. Meulemans A, Poulain B, Baux G, Tauc L. Changes in serotonin concentration in a living neurone: a study by on-line intracellular voltammetry. Brain Res 414: 158-162, 1987. (Pubitemid 17103556)
36. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Pena-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 52: 843-850, 2008.
37. Miller JD, Weiss RM, Serrano KM, Brooks RM, Berry CJ, Zimmerman K, Young SG, Heistad DD. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 119: 2693-2701, 2009.
38. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med 348: 1005-1015, 2003. (Pubitemid 36302245)
39. Moller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J, Connolly HM. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 112: 3320-3327, 2005. (Pubitemid 43739378)
40. Ogden KK, Falck JR, Watts SW. The cytochrome p450 inhibitor ketoconazole potentiates 5-hydroxytryptamine-induced contraction in rat aorta. J Pharmacol Exp Ther 323: 606-613, 2007.
41. Olson EB Jr, Ghias-Ud-Din M, Rankin J. Serotonin uptake and metabolism in isolated, perfused fetal, newborn and adult rabbit lungs. Lung 161: 173-179, 1983.
42. Pizzinat N, Girolami JP, Parini A, Pecher C, Ordener C. Serotonin metabolism in rat mesangial cells: involvement of a serotonin transporter and monoamine oxidase A. Kidney Int 56: 1391-1399, 1999. (Pubitemid 29451246)
43. Rajamannan NM, Caplice N, Anthikad F, Sebo TJ, Orszulak TA, Edwards WD, Tajik J, Schwartz RS. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 10: 827-831, 2001. (Pubitemid 33133581)
44. Richter G, Stockmann F, Conlon JM, Creutzfeldt W. Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology 91: 612-618, 1986. (Pubitemid 16045410)
45. Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A, Ghigo D. Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 279: 47726-47731, 2004. (Pubitemid 39540920)
46. Rigby SE, Basran J, Combe JP, Mohsen AW, Toogood H, van TA, Sutcliffe MJ, Leys D, Munro AW, Scrutton NS. Flavoenzyme catalysed oxidation of amines: roles for flavin and protein-based radicals. Biochem Soc Trans 33: 754-757, 2005. (Pubitemid 41160857)
47. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92: 790-795, 1995.
48. Roth BL. Drugs and valvular heart disease. N Engl J Med 356: 6-9, 2007.
49. Rothman RB, Zolkowska D, Baumann MH. Serotonin (5-HT) transporter ligands affect plasma 5-HT in rats. Ann NY Acad Sci 1139: 268-284, 2008.
50. Ryan MJ, Didion SP, Davis DR, Faraci FM, Sigmund CD. Endothelial dysfunction and blood pressure variability in selected inbred mouse strains. Arterioscler Thromb Vasc Biol 22: 42-48, 2002.
51. Scrutton NS. Chemical aspects of amine oxidation by flavoprotein enzymes. Nat Prod Rep 21: 722-730, 2004.
52. Setola V, Roth BL. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on fen-phen. Expert Opin Drug Metab Toxicol 1: 377-387, 2005.
53. Simon AR, Severgnini M, Takahashi S, Rozo L, Andrahbi B, Agyeman A, Cochran BH, Day RM, Fanburg BL. 5-HT induction of c-fos gene expression requires reactive oxygen species and Rac1 and Ras GTPases. Cell Biochem Biophys 42: 263-276, 2005. (Pubitemid 41389400)
54. Simula DV, Edwards WD, Tazelaar HD, Connolly HM, Schaff HV. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 77: 139-147, 2002.
55. Sivasubramaniam SD, Finch CC, Rodriguez MJ, Mahy N, Billett EE. A comparative study of the expression of monoamine oxidase-A and -B mRNA and protein in non-CNS human tissues. Cell Tissue Res 313: 291-300, 2003. (Pubitemid 37260436)
56. Ulus IH, Maher TJ, Wurtman RJ. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol 59: 1611-1621, 2000.
57. Vindis C, Seguelas MH, Lanier S, Parini A, Cambon C. Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase. Kidney Int 59: 76-86, 2001. (Pubitemid 32055216)
58. Weyler W, Hsu YP, Breakefield XO. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47: 391-417, 1990.
59. Wouters J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem 5: 137-162, 1998. (Pubitemid 28183854)
60. Zadikoff C, Duong-Hua M, Sykora K, Marras C, Lang A, Rochon P. Pergolide associated cardiac valvulopathy based on Ontario administrative data. Can J Neurol Sci 35: 173-178, 2008. (Pubitemid 351831053)
61. Zadikoff C, Rochon P, Lang A. Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 33: 27-33, 2006.
62. Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther 318: 604-610, 2006. (Pubitemid 44061235)